PBR Nachrichten

 

Under the agreement, Biocodex will hold an exclusive worldwide licence to develop and commercialise Batten-1, which has been developed by THX Pharma for juvenile Batten disease (CLN3). Additionally, The post THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs appeared first on Pharmaceutical Business review....

The companies plan to jointly develop at least two research and development (R&D) programmes using Insilico Medicine's AI platform alongside CMS' expertise in clinical development. Under the agreement, The post Insilico and CMS launch drug discovery collaborations for CNS diseases appeared first on Pharmaceutical Business review....

The FDA accepted the gene therapy's application under the accelerated approval pathway in May 2025. The CRL indicated that the FDA agreed in principle with the study protocol The post REGENXBIO receives FDA response for RGX-121 application appeared first on Pharmaceutical Business review....

The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation. Through this arrangement, Takeda will The post Takeda and Iambic announce $1.7bn deal to advance small molecule programmes appeared first on Pharmaceutical Business review....

The partnership represents the seventh agreement between the two companies and aims to expedite the delivery of new therapies to patients worldwide. Under the agreement, Innovent will utilise The post Innovent and Lilly to advance new oncology and immunology medicines appeared first on Pharmaceutical Business review....

Set to open in 2029, the facility will cover approximately 466,000ft² and accommodate 1,000 employees. The centre will connect with other Novartis global research locations in Basel, Switzerland, The post Novartis starts construction on new research facility in San Diego, US appeared first on Pharmaceutical Business review....

The company's fourth quarter revenues increased 1% to $12.5bn, and its growth portfolio surged 16% to $7.4bn. BMS reported non-GAAP earnings per share (EPS) of $6.15 for the The post BMS reports flat revenue growth for full-year 2025 appeared first on Pharmaceutical Business review....

This contract enables Apotex to seek marketing authorisation and distribute the product in the country through its branded medicine division, Searchlight Pharma, once regulatory approval is secured. Grünenthal The post Apotex and Grünenthal sign deal for Nebido Canadian distribution appeared first on Pharmaceutical Business review....

Under this agreement, Everest Medicines will make potential regulatory and commercial milestone payments of up to 1.04bn yuan ($149m) and an upfront payment of 200m yuan. Furthermore, Micot The post Everest Medicines and Micot partner on MT1013 commercialisation appeared first on Pharmaceutical Business review....

The agreement aims to advance PrimeGen US's stem cell research and development and will provide access to public markets capital for progressing clinical studies, regulatory activities, and potential The post PrimeGen US and DT Cloud Star sign $1.5bn merger agreement appeared first on Pharmaceutical Business review....

The designation covers adults with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutant, hormone receptor positive, HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression after treatment with The post Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer appeared first on Pharmaceutical Business review....

Samsung Biologics is set to become part of CEPI's Vaccine Manufacturing Facility Network (VMFN), aiming to speed up the availability of protein-based vaccines and improve access during outbreaks The post CEPI and Samsung Biologics partner to boost global vaccine preparedness appeared first on Pharmaceutical Business review....

The deal grants Genentech exclusive global rights to develop and commercialise the selected RNAi programme. According to the contract, SanegeneBio will manage early development activities while Genentech will The post SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal appeared first on Pharmaceutical Business review....

The CHMP recommends the use of niraparib and abiraterone acetate with prednisone or prednisolone (AAP), along with androgen deprivation therapy (ADT), specifically for patients with metastatic hormone-sensitive prostate The post CHMP grants positive opinion for J&J's Akeega use appeared first on Pharmaceutical Business review....

The therapy aims to treat Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more. The CRL highlights deficiencies in human factors validation for Anaphylm, such The post Aquestive receives FDA CRL for Anaphylm allergic reaction treatment appeared first on Pharmaceutical Business review....

The CHMP recommends the use of niraparib and abiraterone acetate with prednisone or prednisolone (AAP), along with androgen deprivation therapy (ADT), specifically for patients with metastatic hormone-sensitive prostate The post CHMP grants positive opinion for J&J's Akeega use appeared first on Pharmaceutical Business review....

The initiative aims to speed up the development of platform-based genetic therapies for rare diseases in the US. It also aims to create a scalable model to deliver The post CIRM unveils RAPID funding programme for rare diseases appeared first on Pharmaceutical Business review....

As part of this agreement, Boehringer Ingelheim will utilise IQVIA's data-as-a-service (DaaS+) technology to advance its global commercial data transformation, aiming to streamline data management and analytics across The post IQVIA and Boehringer Ingelheim collaborate on therapeutic data transformation appeared first on Pharmaceutical Business review....

The partnership will focus on creating treatments intended to restore immune homeostasis and deliver durable remission for patients, avoiding the generalised immune suppression associated with existing therapies. Under The post Repertoire and Lilly join hands on autoimmune disease therapies appeared first on Pharmaceutical Business review....

The financing includes a €20m strategic investment from Sanofi and €40m from existing and new investors such as Artal (advised by Invus), Redmile Group, Cormorant Asset Management, Sofinnova The post Sensorion announces $71.9m reserved offering to expand gene therapy pipeline appeared first on Pharmaceutical Business review....